ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lau, C.L.
Right arrow Articles by Patterson, G.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lau, C.L.
Right arrow Articles by Patterson, G.A.
Eur Respir J 2003; 22:57s-64s
Copyright ©ERS Journals Ltd 2003

Current status of lung transplantation

C.L. Lau and G.A. Patterson

Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO, USA

CORRESPONDENCE: G.A. Patterson, Suite 3108, Queeny Tower, P.O. Box 8234, St Louis, MO, 63110, USA. Fax: 1 3143620328. E-mail: lauch@msnotes.wustl.edu

Keywords: bronchiolitis obliterans syndrome, donor selection, lung transplantation, reperfusion injury

Received: February 28, 2003
Accepted April 28, 2003

Two decades have passed since the first successful clinical lung transplant was performed in 1983, and, in the interim, lung transplantation has become the preferred treatment option for a variety of end-stage pulmonary diseases. Remarkable progress has been made in the field through refinement of technique and improved understanding of transplant immunology and microbiology.

Unfortunately, donor shortages continue to limit the more widespread application of lung transplantation. In order to address this issue, marginal donors, living lobar and split lung donor techniques, and nonheartbeating donors have been used clinically to increase the number of donor lungs available.

Chronic rejection of the lung allograft is currently the major hurdle limiting long-term survival. To date, prevention of known risk factors and treatment strategies have not lessened the devastating toll this process has on lung transplant survival. Better understanding of the cause of chronic rejection is needed in order to develop novel strategies for its treatment. Promotion of immune tolerance is a promising area that could potentially eliminate chronic rejection.

The present article discusses recent advances in lung transplantation. It also details the major issues facing the field today. Only through continued clinical and experimental investigation will lung transplantation eventually reach its full potential.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the European Respiratory Society.